These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

294 related items for PubMed ID: 8497847

  • 21. A new approach in the study of the molecular and cellular events implicated in heparin-induced thrombocytopenia. Formation of leukocyte-platelet aggregates.
    Khairy M, Lasne D, Brohard-Bohn B, Aiach M, Rendu F, Bachelot-Loza C.
    Thromb Haemost; 2001 Jun; 85(6):1090-6. PubMed ID: 11434690
    [Abstract] [Full Text] [Related]

  • 22. Validation of whole blood impedance aggregometry as a new diagnostic tool for HIT: results of a large Australian study.
    Morel-Kopp MC, Tan CW, Brighton TA, McRae S, Baker R, Tran H, Mollee P, Kershaw G, Joseph J, Ward C, ASTH Clinical Trials Group.
    Thromb Haemost; 2012 Mar; 107(3):575-83. PubMed ID: 22234599
    [Abstract] [Full Text] [Related]

  • 23. Laboratory diagnosis of immune heparin-induced thrombocytopenia.
    Warkentin TE, Heddle NM.
    Curr Hematol Rep; 2003 Mar; 2(2):148-57. PubMed ID: 12901146
    [Abstract] [Full Text] [Related]

  • 24. Heparin-induced thrombocytopenia: an autoimmune disorder regulated through dynamic autoantigen assembly/disassembly.
    Cines DB, Rauova L, Arepally G, Reilly MP, McKenzie SE, Sachais BS, Poncz M.
    J Clin Apher; 2007 Feb; 22(1):31-6. PubMed ID: 17285619
    [Abstract] [Full Text] [Related]

  • 25. Cardiac surgery in patients with heparin-induced thrombocytopenia using preoperatively determined dosages of iloprost.
    Antoniou T, Kapetanakis EI, Theodoraki K, Rellia P, Thanopoulos A, Kotiou M, Zarkalis D, Alivizatos P.
    Heart Surg Forum; 2002 Feb; 5(4):354-7. PubMed ID: 12538117
    [Abstract] [Full Text] [Related]

  • 26. Human anti-heparin-platelet factor 4 antibodies are capable of activating primate platelets: towards the development of a HIT model in primates.
    Ahmad S, Jeske WP, Walenga JM, Aldabbagh A, Iqbal O, Fareed J.
    Thromb Res; 2000 Oct 01; 100(1):47-54. PubMed ID: 11053616
    [Abstract] [Full Text] [Related]

  • 27. Risk of heparin-induced thrombocytopenia from heparin-bonded vascular prostheses.
    Mureebe L, Graham JA, Bush RL, Silver D.
    Ann Vasc Surg; 2007 Nov 01; 21(6):719-22. PubMed ID: 17980795
    [Abstract] [Full Text] [Related]

  • 28. Contribution of platelet microparticles generation assay to the diagnosis of type II heparin-induced thrombocytopenia.
    Mullier F, Bailly N, Cornet Y, Dubuc E, Robert S, Osselaer JC, Chatelain C, Dogné JM, Chatelain B.
    Thromb Haemost; 2010 Jun 01; 103(6):1277-81. PubMed ID: 20390228
    [No Abstract] [Full Text] [Related]

  • 29. Heparin-induced thrombocytopenia: pathophysiology.
    Kibbe MR, Rhee RY.
    Semin Vasc Surg; 1996 Dec 01; 9(4):284-91. PubMed ID: 8958604
    [Abstract] [Full Text] [Related]

  • 30. Heparin-induced thrombocytopenia after liver transplantation.
    Kaneko J, Sugawara Y, Tamura S, Togashi J, Matsui Y, Makuuchi M.
    Transplant Proc; 2008 Jun 01; 40(5):1518-21. PubMed ID: 18589141
    [Abstract] [Full Text] [Related]

  • 31. Heparin-induced thrombocytopenia platelet aggregation studies in the presence of heparin fractions or semi-synthetic analogues of various molecular weights and anticoagulant activities.
    Blockmans D, Bounameaux H, Vermylen J, Verstraete M.
    Thromb Haemost; 1986 Feb 28; 55(1):90-3. PubMed ID: 3518134
    [Abstract] [Full Text] [Related]

  • 32. Laboratory testing for the antibodies that cause heparin-induced thrombocytopenia: how much class do we need?
    Warkentin TE, Sheppard JA, Moore JC, Moore KM, Sigouin CS, Kelton JG.
    J Lab Clin Med; 2005 Dec 28; 146(6):341-6. PubMed ID: 16310517
    [Abstract] [Full Text] [Related]

  • 33. Heparin-induced thrombocytopenia.
    Fabris F, Luzzatto G, Stefani PM, Girolami B, Cella G, Girolami A.
    Haematologica; 2000 Jan 28; 85(1):72-81. PubMed ID: 10629596
    [Abstract] [Full Text] [Related]

  • 34. Testing for heparin-induced thrombocytopenia antibodies.
    Warkentin TE, Sheppard JA.
    Transfus Med Rev; 2006 Oct 28; 20(4):259-72. PubMed ID: 17008164
    [Abstract] [Full Text] [Related]

  • 35. Heparin induced platelet aggregation: in vitro confirmation of thrombotic complications associated with heparin therapy.
    Hussey CV, Bernhard VM, McLean MR, Fobian JE.
    Ann Clin Lab Sci; 1979 Oct 28; 9(6):487-93. PubMed ID: 518011
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Effect of SR121566A, a potent GP IIb-IIIa antagonist, on the HIT serum/heparin-induced platelet mediated activation of human endothelial cells.
    Herbert JM, Savi P, Jeske WP, Walenga JM.
    Thromb Haemost; 1998 Aug 28; 80(2):326-31. PubMed ID: 9716161
    [Abstract] [Full Text] [Related]

  • 39. Platelet aggregation studies for the diagnosis of heparin-induced thrombocytopenia.
    Isenhart CE, Brandt JT.
    Am J Clin Pathol; 1993 Mar 28; 99(3):324-30. PubMed ID: 8447295
    [Abstract] [Full Text] [Related]

  • 40. When heparin causes thrombosis: significance, recognition, and management of heparin-induced thrombocytopenia in dialysis patients.
    Chang JJ, Parikh CR.
    Semin Dial; 2006 Mar 28; 19(4):297-304. PubMed ID: 16893407
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.